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Background: The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first
introduced in mass vaccination campaigns of the 1-29-year-olds in Burkina Faso in 2010. The aim of this study was
to genetically characterize meningococcal isolates circulating in Burkina Faso before and up to 13 months after
MenAfriVac mass vaccination.
Methods: A total of 1,659 meningococcal carriage isolates were collected in a repeated cross-sectional carriage
study of the 1-29-year-olds in three districts of Burkina Faso in 2010 and 2011, before and up to 13 months after
mass vaccination. Forty-two invasive isolates were collected through the national surveillance in Burkina Faso in the
same period. All the invasive isolates and 817 carriage isolates were characterized by serogroup, multilocus
sequence typing and porA-fetA sequencing.
Results: Seven serogroup A isolates were identified, six in 2010, before vaccination (4 from carriers and 2 from
patients), and one in 2011 from an unvaccinated patient; all were assigned to sequence type (ST)-2859 of the ST-5
clonal complex. No NmA carriage isolate and no ST-2859 isolate with another capsule were identified after
vaccination. Serogroup X carriage and disease prevalence increased before vaccine introduction, due to the
expansion of ST-181, which comprised 48.5% of all the characterized carriage isolates. The hypervirulent serogroup
W ST-11 clone that was responsible for most of meningococcal disease in 2011 and 2012 was not observed in
2010; it appeared during the epidemic season of 2011, when it represented 40.6% of the serogroup W
carriage isolates.
Conclusions: Successive clonal waves of ST-181 and ST-11 may explain the changing epidemiology in Burkina Faso
after the virtual disappearance of NmA disease and carriage. No ST-2859 strain of any serogroup was found after
vaccination, suggesting that capsule switching of ST-2859 did not occur, at least not during the first 13 months
after vaccination.
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In the African meningitis belt, a sub-Saharan region
stretching from Senegal to Ethiopia [1,2], the popula-
tions are affected by annual outbreaks of meningococcal
meningitis during the dry season. Devastating epidemics
with peak incidence approaching 1,000 cases/100,000 [3]
occur every 8–12 years. Most of the epidemics have
been attributed to Neisseria meningitidis serogroup A
(NmA), but some countries have also experienced NmX
and NmW epidemics [4,5]. Burkina Faso, a West-African
country of approximately 16 million inhabitants, is among
the most affected ones, and NmA of sequence types (ST)-
5, ST-7 and ST-2859 have been successively responsible
for major epidemics [4,6]. In 2002, Burkina Faso was the
first African country to experience a serogroup W epi-
demic, due to the hypervirulent ST-11 clone, probably
imported from Saudi Arabia [7-10]. In 2006 a major
serogroup X epidemic caused by ST-181 affected the
neighbouring country Niger [11,12] and the clone later
spread to Burkina Faso [13].
Polysaccharide (Ps) vaccines, used to stop ongoing epi-
demics [14,15], provide limited and relatively brief pro-
tection, do not induce immunological memory and do
not protect against carriage [16]. Thus, they have not
been successful in preventing the occurrence of new out-
breaks. Conjugate vaccines are immunogenic in young
children and generate immunological memory. The conju-
gate vaccines’ ability to prevent carriage acquisition is also
another major advantage, as transmission of the bacterium
is reduced.
A new NmA polysaccharide-tetanus toxoid conju-
gated vaccine, MenAfriVac, developed to eliminate
NmA epidemics in the meningitis belt, was first intro-
duced on a national scale in Burkina Faso [17-21].
Following a pilot introduction in the district of Kaya
in September 2010, the whole 1-29-year-old popula-
tion in Burkina Faso was vaccinated in December
2010 [21]. The rate of NmA disease and carriage was
substantially reduced and herd immunity was gener-
ated [22,23]. One of the concerns when introducing a
monovalent vaccine is the possibility for serogroup re-
placement or capsule switch [24-27]. Capsule switch
has been documented in several countries [28-32] and
the importance of molecular methods in post-vaccination
surveillance has been emphasized [29,32,33].
To better understand the impact of implementing a
monovalent meningococcal conjugate vaccine in the
meningitis belt, including the potential for capsule swit-
ching, and to follow the evolution of circulating menin-
gococcal isolates, we characterized invasive and carriage
isolates collected in Burkina Faso in 2010 and 2011,
before and after MenAfriVac introduction. We present
here the molecular characteristics of circulating menin-
gococci up to one year after vaccination.Methods
Ethics
The collection of oropharyngeal samples in Burkina Faso
was approved by the Norwegian Regional Committee for
Medical Research Ethics, Southern Norway, the Ethical
Committee for Health Research in Burkina Faso and the
Internal Review Board at Centers for Disease Control
and Prevention (CDC), Atlanta, USA. The collection of
CSF samples was performed within the Burkina Faso na-
tional healthcare system as part of the national surveil-
lance and did not require ethical clearance.
Meningococcal isolates from healthy carriers
In a repeated cross-sectional study performed in 2010
and 2011 oropharyngeal swabs were collected from a
representative proportion of 1-29-year-old residents of
three health districts in Burkina Faso; the urban district
of Bogodogo, and the rural districts of Dandé and Kaya,
during five sampling campaigns, named S5-S9, as de-
scribed [22,34]. During each of the campaigns, > 5000
individuals aged 1–29 years were enrolled within a
4-week period after their individual written informed
consent, or that of their parent or guardian for children
below 18 years. A total of 25,521 samples were obtained.
Due to an earlier vaccination with MenAfriVac in the
district of Kaya (September 2010) than in the rest of the
country (December 2010), 3428 of the samples were col-
lected from unvaccinated districts.
Swabbing and laboratory analysis aiming at identifying
meningococci were performed by the staff of micro-
biological laboratories in Burkina Faso: the Centre
Hospitalier Universitaire Pédiatrique Charles de Gaulle,
Ouagadougou for Bogodogo; the Centre Hospitalier
Universitaire Souro Sanou, Bobo-Dioulasso for Dandé;
and the Centre Hospitalier Universitaire Yalgado,
Ouagadougou for Kaya, as previously described [34].
Isolates suspected to be N. meningitidis were sent to
Norwegian Institute of Public Health (NIPH) in Oslo,
Norway for confirmatory analysis and molecular cha-
racterization. All the isolates confirmed as N. meningitidis
were subject to molecular characterization with the excep-
tion of 842 serogroup X isolates collected in the district of
Kaya. Due to very high carriage rates of serogroup X men-
ingococci in Kaya about one fourth (273/1115) of the
serogroup X isolates were randomly selected for molecu-
lar characterization (range, 15.1 - 52.5% per campaign).
Invasive meningococcal isolates
Cerebrospinal fluid (CSF) samples were collected from
42 cases of meningitis in Burkina Faso, as part of the
normal case investigation. CSF samples from the epide-
mic season of 2010 were sent to the WHO Collaborating
Centre for Reference and Research on Meningococci at
NIPH in trans-isolate medium [35]. Samples from 2011
Table 1 Number of isolates subjected to molecular
characterization by district and sampling campaign
Sampling campaign S5 S6 S7 S8 S9 Total
District
Bogodogo 49 a) 22 38 31 18 158
Dandé 63 a) 72 48 71 42 296
Kaya 103 72 48 80 60 363
Total 215 166 134 182 120 817
a) Unvaccinated district at the time of S5.
Table 2 Number of genotyped carriage isolates from
Burkina Faso before and after MenAfriVac vaccination, by
serogroup
Pre-vaccination Post-vaccination
District B D B D K Total
Serogroup
A 0 4 0 0 0 4
B 0 0 0 0 1 1
C 2 0 1 0 2 5
W 5 5 23 58 11 102
X 29 21 42 42 273 407
Y 5 31 16 114 54 220
NG 8 2 27 19 22 78
Total 49 63 109 233 363 817
Isolates were obtained from the districts of Bogodogo (B), Dandé (D) and
Kaya (K).
NG nonserogroupable.
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taire Pédiatrique Charles de Gaulle, Ouagadougou and
meningococci were sent to NIPH frozen on dry-ice.
Characterization of meningococcal isolates
Standard laboratory methods were used to identify men-
ingococci [34] and the serogroup was primarily deter-
mined by slide agglutination (Remel, GA, USA). DNA
was isolated by suspending 1 loop of bacteria in 200 μl
Tris-EDTA (TE) buffer, pH 8.0, heating at 95°C for
10 minutes and centrifugation at 16,000 × g for 5 min.
Capsule gene PCR [36] was applied for serogroup deter-
mination of isolates non-serogroupable by slide agglutin-
ation. Multilocus sequence typing (MLST) using seven
housekeeping gene fragments [37] was performed with
oligonucleotide primers, as recommended on the MLST
website (http://pubmlst.org/neisseria/). Classification by
outer membrane protein PorA and FetA variants was
done by DNA sequencing of the porA and fetA genes
[38,39]. New MLST alleles, STs, PorA and FetA vari-
ants were submitted to the MLST database (http://
pubmlst.org/neisseria/). For culture-negative CSF-samples,
the genotypic characterization was limited to capsule
gene PCR and porA sequencing following a nested
porA-PCR [40].
The invasive isolates were tested for antibiotic suscep-
tibility by determination of minimal inhibitory concen-
trations (MIC) of penicillin G, ciprofloxacin, ceftriaxone,
rifampicin, tetracycline, chloramphenicol and sulpho-
namides using Etest (AB Biodisk, Solna, Sweden). The
isolates were classified as susceptible, intermediate or re-
sistant according to the breakpoints from the European
Committee on Antibiotic Susceptibility Testing (www.
eucast.org).
Results
Sample collection
A total of 1,659 meningococcal carriage isolates was re-
trieved, of which 112 were from unvaccinated districts
in 2010 and 1,547 from vaccinated districts in 2010–
2011. From a total of 1,205 isolates originating from
Kaya, 1,115 were NmX. Of these a subset of 273 isolates
was genotyped: 80 from sampling S5, 50 from S6, 33
from S7, 62 from S8 and 48 from S9, representing
20.2%, 17.5%, 15.1%, 52.5% and 51.6% of the NmX iso-
lates, respectively. All the isolates from Bogodogo (158)
and Dandé (296) and all the non-NmX isolates from
Kaya (90) were subject to genotypic characterization.
Hence, a total of 817 carriage isolates was genetically
characterized. The number of characterized isolates by
campaign and site is shown in Table 1.
Forty-two invasive isolates from Burkina Faso were
sent to NIPH, 24 from 2010 before the vaccination cam-
paign and 18 from 2011. Of these, 28 were recovered byculture and could be analyzed by MLST, porA and fetA
sequencing. The remaining 14 samples were tested by
capsule gene PCR and porA sequencing.
Molecular characterization of carriage isolates
The 817 carriage isolates comprised 407 NmX (49.8%),
220 NmY (26.9%), 102 NmW (12.5%), 78 (9.5%) non-
serogroupable Nm (NmNG), 5 NmC (0.6%), 4 NmA
(0.5%) and a single NmB isolate (Table 2). The isolates
were assigned to 28 different STs of which 20 belonged
to 11 defined ST-complexes (Additional file 1: Table S1).
We identified 4 new alleles for the housekeeping genes
included in the MLST scheme, 8 new STs, 5 new PorA
variants and 4 new FetA variants, all submitted to the
MLST database (http://pubmlst.org/neisseria/).
ST-181 of the ST-181 clonal complex dominated with
396 (48.5%) isolates (Additional file 1: Table S1). The
ST-181 isolates were NmX (n= 388) or NmNG (n=8).
The dominant PorA/FetA combination of the ST-181
isolates was P1.5-1,10-1; F1-31 (91.0%), independently of
the serogroup. In Kaya, 98.1% of the 273 genotyped
NmX isolates were assigned to ST-181, 1.5% to ST-5789
and 0.4% (one isolate) to ST-9359. Both ST-5789 and
ST-9359 are single locus variants (SLV) of ST-181 at the
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proportion of NmX isolates from Kaya with ST-181 to
the total number of NmX isolates recovered in each
campaign, as many as 1,092 NmX isolates from that dis-
trict were likely ST-181. With 58 isolates from Bogodogo
and 62 from Dandé the total number of NmX ST-181
isolates was likely 1,212, or 73.1% of the carriage isolates
in all three districts.
ST-4375 of the ST-23 complex was the second domin-
ating ST representing 15.9% of the genotyped isolates
(Additional file 1: Table S1). It included 129 NmY and 1
NmNG. The ST-23 clonal complex was also represented
by a single strain assigned to ST-9353, a SLV of ST-4375
at the adk locus and first identified in this study. Within
the ST-23 complex, the dominating PorA/FetA combin-
ation was P1.5-1,2-2; F5-8 (96.9%) independently of ST
and serogroup.
Isolates assigned to ST-2881 of the ST-175 complex
represented 9.2% of the isolates and were serogrouped
as W (n=52), Y (n=12) or NG (n=11) (Additional file 1:
Table S1). Among the ST-2881 isolates, 84% expressed
the PorA variant P1.5-1,2-36, 92% the FetA variant F5-1
and 76% the combination P1.5-1,2-36; F5-1. The ST-175
complex was also represented by the ST-8638 expressing
either a W (n=4) or Y (n=1) capsule. All the ST-8638
isolates were characterized as P1.5-1,2-36; F5-1.
ST-767 of the ST-167 complex included 56 NmY, 1
NmB, 1 NmX and 4 NmNG isolates and accounted for
7.6% of the genotyped strain collection (Additional file 1:
Table S1). The PorA/FetA combination P1.5-1,2-2; F5-8
was expressed by 88.7% of the ST-767 isolates. Fifteen of
16 isolates assigned to the two other STs of the ST-167
clonal complex, the ST-2880 and the ST-7375 expressed
the same PorA/FetA combination.
A total of 42 (5.1%) ST-11 isolates were found, of
which 41 were NmW and one was NmNG (Additional
file 1: Table S1). The ST-11 complex was also repre-
sented by two ST-9358 isolates identified in the district
of Dandé during the sampling campaign S8. ST-9358 is
a SLV of ST-11 at the abcZ locus. All the ST-11 complex
isolates were P1.5,2. Fet A variant F1-1 was found for
95.6% of them and F5-4 on the remaining two isolates.
In contrast to other major STs that were found in all
three districts, ST-11 was only present in the districts of
Bogodogo and Dandé.
NmA carriage was only found in Dandé before vaccine
introduction. Four isolates were identified and all were
ST-2859; P1.20,9; F3-1. None of the isolates assigned to
ST-2859 or classified as P1.20,9 or F3-1 expressed any
other serogroup than A.
ST distribution of carriage isolates over time
ST-2859, expressing a serogroup A capsule, was present
in the non-vaccinated district of Dandé in October-November 2010, but was not seen after introduction of
MenAfriVac (Figure 1). The other two genotypes known
to cause outbreaks in sub-Saharan Africa, ST-181 and
ST-11, were present in carriers after vaccine intro-
duction. However, NmX ST-181 was circulating already
since 2009 [34], while NmW ST-11 was detected only
after vaccine introduction (Figure 1). The NmW ST-11
clone was first detected in the district of Dandé from S6
and then in Bogodogo from S7 (Figure 2). A non-
groupable ST-11; P1.5-2; F1-1 isolate was also detected
in Bogodogo during sampling S6.
Among the NmW isolates 40.6% were ST-11 and
50.5% were ST-2881. The distribution of the two do-
minant genotypes of NmW isolates was not constant in
time. ST-11 carriage peaked at S7 in the districts of
Bogodogo and Dandé while carriage of ST-2881 in-
creased from S8 onwards (Figure 2).
Molecular characterization of invasive isolates
The invasive isolates belonged to 5 STs (Table 3). All the
NmA isolates were ST-2859; P1.20,9; F3-1. A single
serogroup A isolate from a non-vaccinated 10-year old
child was found after vaccine introduction. The NmX
isolates were all ST-181; P1.5-1,10-1; F1-31 or F5-69.
Fourteen culture-negative samples were P1.5-1,10-1 and
likely represented the same NmX clone. Before introduc-
tion of MenAfriVac, a single NmW was analysed and
characterized as ST-8638; P1.5-1,2-36; F5-1. After vac-
cine introduction, all the NmW isolates were ST-11;
P1.5,2; F1-1.
When comparing the genotypes of carriage isolates
with those of invasive isolates, we found that the clones
responsible for disease were the dominant genotypes
of the corresponding serogroups among the carriage
isolates; ST-2859; P1.5-1,2-2; F3-1 for NmA, ST-181;
P1.5-1,10-1; F1-31 for NmX, and ST-11; P1.5,2; F1-1
for NmW.
Antibiotic susceptibility of invasive isolates
All the 28 culture positive isolates were susceptible to
ciprofloxacin (MIC range, 0.002 - 0.008), ceftriaxone
(MIC range, <0.002 - 0.003), rifampicin (MIC range,
0.004 - 0.19), and chloramphenicol (MIC range, 0.5 - 2).
Five serogroup W isolates were of intermediate resistance
to penicillin G, all the remaining isolates were susceptible.
The serogroup A isolates were resistant to tetracycline
(MIC range 3 - 4) while the other serogroups were not
(MIC range, 0.125 - 0.19). All serogroup A and W isolates
were resistant to sulphonamides (MIC 24 - >1024).
Discussion
In this study we present the molecular epidemiology of
meningococcal carriage isolates collected in three dis-
tricts in Burkina Faso immediately before and up to 13
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Figure 1 Genotypes of meningococcal carriage and invasive isolates from Burkina Faso before and after MenAfriVac vaccination. The
figure represents the time points when different sequence types (ST) of carriage isolates (dark grey) and invasive isolates (red) were detected in
the carriage study or national surveillance [41], respectively. Each ST was either detected or not detected (blank), or data was unavailable (grey).
Horizontal lines separate ST complexes. The vertical line represents vaccination: during sampling campaign S5, the districts of Bogodogo (B) and
Dandé (D) were not yet vaccinated while the Kaya district (K) had introduced the vaccine. UA, unassigned to any ST complex. * One single case
of serogroup A disease was reported in 2011.
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gate vaccine, in comparison with isolates recovered from
patients in 2010 and 2011. Our study showed that the
relatively high incidence of NmX disease in 2010–2011
was caused by the same clone (ST-181) found among
carriers and patients before vaccination, while the hy-
pervirulent NmW ST-11 clone seemed to have been
reintroduced in Burkina Faso after mass vaccination. We
did not find evidence that the NmA ST-2859 cloneunderwent a capsule switch up to 13 months after vac-
cination either among isolates from carriers or patients.
The collection of invasive strains used to characterize
meningococcal disease in Burkina Faso was not a com-
plete or systematic collection taking into account the
disease incidence or the geographic distribution of cases.
Of 6732 suspected cases of meningitis reported in Burkina
Faso in 2010, only 467 CSF samples were analyzed; 130
samples were Nm [41] and of those, 24 isolates sent to the
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Figure 2 Carriage prevalence of Neisseria meningitidis serogroup X ST-181 and serogroup W ST-11 and ST-2881 in three Districts of
Burkina Faso during the sampling campaigns S1-S9, 2009–2011. Data from S1 to S4 are from a previously published study [34]. Black lines
with boxes, serogroup X ST-181. Dotted lines with triangle, serogroup W ST-2881. Dotted lines with cross, serogroup W ST-11.
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proved surveillance [23,42], of the 3875 cases reported in
2011, as many as 3125 CSF samples were analyzed; 257
samples were Nm, but only 18 Nm isolates were sent to
the WHO reference laboratory. PCR was introduced in
Burkina Faso for enhanced laboratory surveillance after
vaccine introduction, which may explain the lesser num-
ber of collected isolates. Although the strain collection is
not completely representative for the meningococcal dis-
ease epidemiology in Burkina Faso, it provides a valuablesource of information, supplementing other research stu-
dies in the same area [13].
The carriage isolates were collected in a multicenter
repeated cross-sectional study among 1-29-year-olds in
three districts in Burkina Faso. Efforts were made to ob-
tain carriage data from a representative portion of the
population, but when comparing these results with the
characteristics of invasive isolates, one should keep in
mind that the invasive isolates were not necessarily
retrieved from the same districts. The carriage study
Table 3 Molecular characteristics of 42 invasive N. meningitidis strains recovered from Burkina Faso in 2010-2011
Year Culture Serogroup CC ST PorA FetA No. of isolates
2010 Pos. A 5 2859 P1.20,9 F3-1 2
Pos. W 175 8638 P1.5-1,2-36 F5-1 1
Pos. X 181 181 P1.5-1,10-1 F1-31 6
Pos. X 181 181 P1.5-1,10-1 F5-69 1
Neg. ND ND ND P1.5-1,10-1 ND 14
2011 Pos. A 5 2859 P1.20,9 F3-1 1
Pos. W 11 11 P1.5,2 F1-1 7
Pos. X 181 181 P1.5-1,10-1 F1-31 4
Pos. X 181 181 P1.5-1,10-1 F5-69 6
CC Clonal Complex, ST Sequence type, Pos. Culture positive, Neg. Culture negative, ND not determined.
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targeted for vaccination, so this study does not describe
characteristics of carriage isolates in < 1 year-olds or >
29-year-olds. A small number of the sampled individuals
had not been vaccinated with MenAfriVac and the im-
pact of mass vaccination on NmA transmission also in
non-vaccinated has been described previously [22].
The genetic diversity of carriage isolates was low and
comparable to that found in 2009 [34], as 96% of the
isolates in both studies were assigned to only 11 differ-
ent STs. Low genetic diversity of meningococcal car-
riage isolates has been found also in other African
countries [43-45], while the diversity is much higher in
Europe [46].
In the post-vaccination period up to 13 months after
MenAfriVac vaccination, the most striking events were
the disappearance of NmA ST-2859, the dominance of
NmX ST-181 and the re-emergence of NmW ST-11.
Our results show that the NmA isolates circulating in
unvaccinated districts in October-November 2010 were
identical to those circulating in 2009 [34] and those re-
sponsible for NmA disease since 2003 [4,5]. After vac-
cination, NmA carriage and disease were significantly
reduced in 2011 [22,23] and this positive trend contin-
ued as no cases of NmA disease were reported in
Burkina Faso in 2012 and after the epidemic season of
2013 [41].
In 2009 NmX carriage prevalence in Burkina Faso was
0.44% and the majority of isolates was assigned to ST-
181 [13]. NmX carriage was almost exclusively detected
in the eastern districts of Bogodogo and Kaya, with a
significant increase of prevalence in Kaya during the
2009 epidemic season [13]. The strong increase of NmX
ST-181 among carriers and patients in all three districts
in 2010 and 2011 and a particularly high carriage preva-
lence of this clone in Kaya is consistent with a spread
from the east to the west after an outbreak in Niger in
2006 [11]. The significant increase of post-vaccination car-
riage has been shown to be independent of MenAfriVacvaccination as both NmX carriage and disease increased
in 2010 before vaccine introduction [22,23]. We here con-
firm that the increase was due to the ST-181 clone already
circulating in 2009 [34].
Our study showed that, after vaccine introduction
NmW ST-11 re-emerged among carriers as well as
patients. The carriage prevalence of NmW in Burkina
Faso in 2009 was 0.34% and all the isolates belonged
to the ST-175 clonal complex; the majority assigned to
ST-2881 [34]. During the sampling campaign S5 in
October-November 2010 NmW was found only in
Bogodogo and Dandé and all the isolates were still
ST-2881. In 2010, before vaccination, only 8 NmW inva-
sive isolates were identified in Burkina Faso [41] and the
only one analyzed by molecular methods was assigned
to the ST-175 clonal complex (Table 1). NmW ST-11
which was last seen in Burkina Faso in 2006 [5] reap-
peared after the country-wide mass vaccination when it
was identified in both carriers and patients. Although
NmW ST-2881 has been reported to cause meningococ-
cal disease [13,45], until now, the potential to cause large
NmW outbreaks has been associated with the hypervi-
rulent ST-11 clone [9].
The circulation of NmW ST-11 exclusively in the dis-
tricts of Bogodogo and Dandé might be related to the
very high carriage prevalence of NmX in Kaya, where up
to 23.6% of the individuals were NmX carriers [22]. As
NmW ST-11 was first recovered in Dandé in February-
March 2011 and then in Bogodogo in May of the same
year, another possibility is that the re-introduction of
ST-11 happened from Mali, as the Dandé district is close
to Mali, and the same NmW ST-11 clone caused disease
in Mali in 2007 and 2009 [5,47]. Surveillance data from
2012 showed that NmW disease further increased in
Burkina Faso and other countries in the meningitis belt
having introduced MenAfriVac [41].
It could be speculated that the change in epidemiology
from A to W disease might be attributed to a serogroup
replacement caused by the major reduction of NmA
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NmA carriage was extremely low [34], vaccine-induced
serogroup replacement is unlikely to occur. Epidemic
waves have been shown to radically change the menin-
gococcal disease epidemiology in many countries [48].
The last NmW outbreak in Burkina Faso was 10 years
ago and the re-emergence of this serogroup fits well
with the cyclic reappearance of larger epidemics [8,41].
One concern when introducing a monovalent vaccine
is that virulent isolates expressing the capsule targeted
by the vaccine may take up genes coding for another
capsule by horizontal gene transfer and evade the im-
mune system [30,31,49]. Capsule switched isolates have
been shown to conserve their virulence [29]. Up to 13
months after MenAfriVac vaccination, we did not ob-
serve any capsule switch among the ST-2859 isolates
studied. As the MenAfriVac conjugate vaccine affected
transmission of the clone [22] the likelihood that the
virulent clone would acquire capsule genes from another
meningococcal isolate was probably decreased. As capsule
switch might occur any time after vaccine introduction, it
is important to continue molecular characterization of iso-
lates retrieved from national surveillance and carriage
studies.
Conclusion
In this study we found that the increase of NmX carriage
and disease in Burkina Faso in 2010 and 2011 was
due to ST-181 and that the NmW ST-11 clone was
probably re-introduced in 2010. Considering the low
pre-vaccination carriage prevalence of NmA [34], these
observations suggest successive clonal waves of ST-181
and ST-11 contributed to the increase of NmX and
NmW disease after MenAfriVac mass vaccination [41],
rather than being a result from the significant decrease
in NmA disease and carriage [22,23]. The epidemic ST-
2859 clone was the only one to cause NmA infections
before MenAfriVac vaccination, and no ST-2859 strain
of any serogroup was found after vaccination, suggesting
that capsule switching of ST-2859 did not occur, at least
yet. After a successful implementation of MenAfriVac
throughout the whole meningitis belt, the time of devas-
tating NmA epidemics will hopefully be over. However,
continued surveillance of disease and carriage and mo-
lecular characterization of meningococcal isolates is
needed to monitor the long-term impact of vaccination,
follow the genetic evolution and antibiotic susceptibility
of meningococci, and to improve vaccine strategies. Fur-
ther development of effective and affordable vaccines
against the emerging serogroups X and W should be
prioritized. The polysaccharide-conjugated vaccine ap-
proach has been successful, but other vaccine strategies
should also be explored. The low genetic diversity of
meningococcal disease-causing isolates in sub-SaharanAfrica and the stability of sub-capsular antigen compo-
sition over time, suggest that such antigens could be
considered in future vaccine formulations, in addition to
conjugate vaccines.
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